Markets
LLY

AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

A generic image of a newspaper with Stock Market as the headline.
Credit: Shutterstock photo

AstraZeneca PLCAZN announced that the European Commission has granted approval to Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of its GLP-1 receptor agonist Bydureon in an improved once-weekly, single-dose pre-filled BCise device for treating patients with type-II diabetes (T2D).

The nod was expected as earlier in June, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion, recommending marketing approval for the new device. Bydureon BCise was approved in the United States in October last year.

The approval of this new formulation of once-weekly Bydureon will allow the use of the drug as an add-on therapy to basal insulin for treating type II diabetes in patients receiving one or more antidiabetic medicines in addition to diet and exercise and with inadequate glycemic control.

Shares of AstraZeneca have returned 11.9% so far this year, outperforming the industry's increase of 5%.

The approval was based on data from the DURATION-NEO-1 and NEO-2 studies, which showed that once-weekly Bydureon BCise led to a reduction of 1.4% in blood sugar levels compared with 1% for twice-daily dose of Byetta (exenatide) injection at 28 weeks. Moreover, the drug achieved a mean weight reduction of 1.5 kg as a monotherapy compared with 1.9 kg pertaining to oral antidiabetic medicines.

Bydureon recorded sales of $155 million in second-quarter 2018. The expanded indication will definitely boost sales of the drug in the future quarters and will help AstraZeneca drive its revenues.

However, Bydureon competes with several other diabetes drugs including Johnson & Johnson's JNJ Invokamet XR, which has achieved better effectiveness in reducing HbA1c levels in clinical studies. Lilly's LLY Trulicity is another GLP-1 receptor agonist available in the market approved for a once weekly dosing regimen.

AstraZeneca PLC Price and Consensus

AstraZeneca PLC Price and Consensus | AstraZeneca PLC Quote

AstraZeneca currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Illumina, Inc. ILMN , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Illumina's earnings estimates have been raised 12.1% for 2018 and 10% for 2019 over the past 60 days. The stock has soared 60.4% so far this year.

Best Electric Car Stock? You'll Never Guess It.

Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!

Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.

See Zacks Best EV Stock Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY JNJ AZN ILMN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More